News
RUBY
--
0.00%
--
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
AmericaNewsHour · 09/08 06:26
Global Phenylketonuria Drugs Market- Analysis By Recent Trends, Development And Growth Forecast To 2027
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
AmericaNewsHour · 09/03 13:51
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell ...
GlobeNewswire · 09/01 13:00
Euclidean Capital LLC Buys 23andMe Holding Co, Snowflake Inc, Nurix Therapeutics Inc, Sells ...
GuruFocus News · 08/23 21:38
BRIEF-Rubius Therapeutics Reports Q2 Results
reuters.com · 08/09 13:21
Rubius Therapeutics' Q2 Net Loss Widens
MT Newswires · 08/09 10:04
Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?
Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/06 15:23
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Zacks.com · 08/06 13:44
BRIEF-Rubius Therapeutics Appoints Dannielle Appelhans As Chief Operating Officer
reuters.com · 07/29 14:39
Rubius Therapeutics appoints new operations chief
Rubius Therapeutics (NASDAQ:RUBY) appoints Dannielle Appelhans as COO, effective August 9, 2021. She will oversee corporate strategy and technical operations. Most recently, Ms. Appelhans served as senior vice president of technical operations and chief
Seekingalpha · 07/29 12:16
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 ...
Insider Monkey · 07/28 17:08
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM) for the treatment of cancer and auto...
GlobeNewswire · 07/22 12:30
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), today announced the publication of p...
GlobeNewswire · 07/15 12:00
Sector Update: Health Care Stocks Higher Late in Thursday Afternoon Session
MT Newswires · 06/24 16:06
Sector Update: Health Care Stocks Slip From Highs as Less Defensive Sectors Gain Favor
MT Newswires · 06/24 13:39
BRIEF-Rubius Therapeutics Announces First Patient Dosed With Rtx-240 In Combination With Keytruda For The Treatment Of Advanced Solid Tumors
reuters.com · 06/23 20:12
Rubius Therapeutics doses first patient in RTX-240 cancer study
Rubius Therapeutics (RUBY) announces that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with Merck's
Seekingalpha · 06/23 20:07
Rubius Therapeutics Reports First Patient Dosed In RTX-240 In Combo With KEYTRUDA In Ongoing Phase 1/2 Trial For Treatment Of Advanced Solid Tumors
Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
Benzinga · 06/23 20:01
Former FDA Commissioner Hahn joins VC firm that helped launch Moderna
Chip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as
Seekingalpha · 06/15 02:50
Webull provides a variety of real-time RUBY stock news. You can receive the latest news about Rubius Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About RUBY
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.